Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 1,001–1,005 of 1,005
Lampe, H., Tam, L., & Hansen, A. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399802 · Cited by 21
“…(mCRPC) with ARSis, a broader range of chemotherapy agents, and Radium-223 radionucleotide treatment (Petrylak et al., 2004; de Bono et al., 2011; Parker et al., 2013; Beer et al., 2014; James et al., 2016; Fizazi et al., 2017; Kyriakopoulos et al., 2018; Armstrong et al., 2019; Chi et al.,…”
BackgroundMattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F. (2024) · Cancers · doi:10.3390/cancers16091643 · Cited by 16
“In a phase III trial, [ 223 Ra]Ra-dichloride, an α emitter that selectively targets bone metastases, improved over-all survival (OS) compared with placebo, in addition to the best standard of care, in men with castration-resistant PCa and bone metastases [17].”
BackgroundCristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1328423 · Cited by 16
“Almost all patients with prostate cancer, the majority of patients with breast cancer, and a large proportion of patients with lung or kidney cancer will develop bone metastases during the advanced stages of their disease [1,2].”
Maurice Dror, C., Chi, K. N., & Khalaf, D. J. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1341 · Cited by 14
“Lastly, the alpha-particle emitting radiopharmaceutical Radium-223, also prolongs survival in patients with predominantly bony metastases (14).”
BackgroundBody, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3697-5 · Cited by 11
“More than 70% of patients with advanced breast cancer [1], up to 90% of patients with advanced prostate cancer [2, 3] and 60% of patients with advanced lung cancer have radiologic evidence of bone Electronic supplementary material The online version of this article (doi:10.”
Background
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.